Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 61,124 Shares of Stock

Key Points

• Bruce Booth, Director of Sionna Therapeutics, sold a total of 61,124 shares on October 17th, taking a 7.91% decrease in his position with a total transaction value of approximately $1.98 million.
• Sionna Therapeutics reported a quarterly loss of ($0.41) earnings per share, surpassing analyst expectations that estimated a loss of ($0.68).
• The stock has shown significant price fluctuation, with a 52-week low of $7.26 and a high of $34.00, currently trading at around $32.20.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Bruce Booth sold 61,124 shares of the company's stock in a transaction on Friday, October 17th. The stock was sold at an average price of $32.37, for a total transaction of $1,978,583.88. Following the completion of the sale, the director owned 711,697 shares of the company's stock, valued at approximately $23,037,631.89. The trade was a 7.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Thursday, October 16th, Bruce Booth sold 169,260 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.35, for a total transaction of $5,475,561.00.
• On Monday, October 20th, Bruce Booth sold 55,985 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.09, for a total transaction of $1,796,558.65.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.61, for a total transaction of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total transaction of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.38, for a total transaction of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.98, for a total transaction of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total transaction of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total transaction of $372,383.28.

Sionna Therapeutics Price Performance

SION traded up $0.27 during trading on Monday, hitting $32.20. 222,456 shares of the company traded hands, compared to its average volume of 325,019. The stock's fifty day moving average is $25.76 and its 200 day moving average is $18.76. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $34.00.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Analyst Ratings Changes

Several equities research analysts have commented on SION shares. Wall Street Zen raised shares of Sionna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Sionna Therapeutics in a report on Wednesday, October 8th. Raymond James Financial started coverage on shares of Sionna Therapeutics in a report on Tuesday, September 2nd. They set a "strong-buy" rating and a $45.00 price objective on the stock. Jones Trading started coverage on shares of Sionna Therapeutics in a report on Monday, September 8th. They set a "buy" rating and a $46.00 price objective on the stock. Finally, Royal Bank Of Canada started coverage on shares of Sionna Therapeutics in a report on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $38.00.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in shares of Sionna Therapeutics in the second quarter worth about $31,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Sionna Therapeutics in the second quarter worth about $45,000. Virtus Investment Advisers LLC purchased a new stake in shares of Sionna Therapeutics in the second quarter worth about $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Sionna Therapeutics in the second quarter worth about $117,000. Finally, New York State Common Retirement Fund bought a new position in shares of Sionna Therapeutics in the second quarter worth approximately $118,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.